Drugs / Pasritamig
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07319871 | Jan 2026 → Jan 2027 expected | prostate neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT07082920 | Jul 2025 → Jan 2027 expected | prostate neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06095089 | Nov 2023 → Jun 2027 expected | prostate neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT05818683 | Apr 2023 → Aug 2027 expected | prostate carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT04898634 | Jul 2021 → Mar 2027 expected | prostate neoplasm | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04644770 | Nov 2020 → Dec 2026 expected | adenocarcinoma, prostate neoplasm | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07225946 | Dec 2025 → Nov 2027 expected | castration-resistant prostate carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT07164443 | Sep 2025 → Dec 2027 expected | prostate carcinoma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pasritamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07164443 ↗ |
| Known as | JNJ-78278343 | “Pasritamig (JNJ-78278343), a T Cell Redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant...” NCT07164443 ↗ |
| Modality | Other / unclassified | “T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2)” NCT04898634 ↗ |
| Route | Intravenous | “JNJ-78278343 will be administered intravenously.” NCT07082920 ↗ |
| Target | KLK2 | “Targeting Human Kallikrein 2 (KLK2)” NCT04898634 ↗ |